FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

GUERCIOLINI ROBERTO 		2. Issuer Name and Ticker or Trading Symbol

Wave Life Sciences Ltd. [ WVE ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
See Remarks
(Last)          (First)          (Middle)

C/O WAVE LIFE SCIENCES LTD.,, 733 CONCORD AVE. 		3. Date of Earliest Transaction (MM/DD/YYYY)

12/7/2016
(Street)

CAMBRIDGE, MA 02138
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares   12/7/2016     M    20000   A $2.47   20000   D    
Ordinary Shares   12/7/2016     M    4000   A $2.47   4000   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Share Option (Right to Buy)   $2.47   12/7/2016     M         20000      (1) 3/22/2025   Ordinary Shares   20000   $0.00   78617   D    
Share Option (Right to Buy)   $2.47   12/7/2016     M         4000      (2) 3/22/2025   Ordinary Shares   4000   $0.00   8629   D    

Explanation of Responses:
( 1)  The incentive share option represented a right to purchase a total of 108,617 ordinary shares, 25% of which became exercisable on March 10, 2016, which was the first anniversary on which the option was granted, and the remaining shares vest in 36 equal monthly installments thereafter.
( 2)  The non-qualified option represented a right to purchase a total of 12,629 ordinary shares, 25% of which became exercisable on March 10, 2016, which was the first anniversary on which the option was granted, and the remaining shares vest in 36 equal monthly installments thereafter.

Remarks:
Senior Vice President, Head of Early Development

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
GUERCIOLINI ROBERTO
C/O WAVE LIFE SCIENCES LTD.,
733 CONCORD AVE.
CAMBRIDGE, MA 02138

See Remarks

Signatures
/s/ Roberto Guerciolini 12/9/2016
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Wave Life Sciences (NASDAQ:WVE)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Wave Life Sciences Charts.
Wave Life Sciences (NASDAQ:WVE)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Wave Life Sciences Charts.